A detailed history of Jpmorgan Chase & CO transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 64,359 shares of EWTX stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,359
Previous 42,833 50.26%
Holding current value
$2.22 Million
Previous $781,000 48.4%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$15.08 - $21.23 $324,612 - $456,996
21,526 Added 50.26%
64,359 $1.16 Million
Q1 2024

May 10, 2024

BUY
$9.25 - $19.97 $25,622 - $55,316
2,770 Added 6.91%
42,833 $781,000
Q4 2023

Feb 12, 2024

SELL
$5.51 - $12.1 $2,429 - $5,336
-441 Reduced 1.09%
40,063 $438,000
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $28,225 - $37,880
4,926 Added 13.85%
40,504 $232,000
Q2 2023

Aug 11, 2023

BUY
$5.71 - $10.29 $23,970 - $43,197
4,198 Added 13.38%
35,578 $275,000
Q1 2023

May 18, 2023

BUY
$6.66 - $11.33 $193,379 - $328,977
29,036 Added 1238.74%
31,380 $209,000
Q1 2023

May 11, 2023

SELL
$6.66 - $11.33 $146,340 - $248,954
-21,973 Reduced 90.36%
2,344 $15,000
Q4 2022

Feb 13, 2023

BUY
$7.58 - $11.08 $34,261 - $50,081
4,520 Added 22.83%
24,317 $217,000
Q3 2022

Nov 14, 2022

SELL
$8.08 - $13.58 $10,600 - $17,816
-1,312 Reduced 6.22%
19,797 $195,000
Q2 2022

Aug 11, 2022

SELL
$5.67 - $9.87 $34,343 - $59,782
-6,057 Reduced 22.3%
21,109 $168,000
Q1 2022

May 11, 2022

BUY
$9.1 - $18.97 $46,919 - $97,809
5,156 Added 23.43%
27,166 $263,000
Q4 2021

Feb 10, 2022

BUY
$14.41 - $22.41 $209,391 - $325,639
14,531 Added 194.29%
22,010 $337,000
Q3 2021

Nov 12, 2021

BUY
$14.11 - $24.1 $105,528 - $180,243
7,479 New
7,479 $124,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $2.18B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.